Jul 06 2008

Biovail Receives FDA Approval For Aplenzin (BVF-033) For The Treatment Of Depression

Published by poster at 8:38 pm under Uncategorized

Biovail Corporation (NYSE: BVF) (TSX: BVF) announced that it has received Approval from the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for Aplenzin™ (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults.
Aplenzin™ is an alcohol-resistant formulation of a new bupropion salt and has been approved in 174mg, 348mg, and 522mg extended-release tablets. The 522mg dosage strength provides patients requiring the maximum allowable dose of bupropion the only single tablet, once-daily option.
Biovail remains in active partnership discussions for the commercialization rights for Aplenzin™ in the United States.
About Biovail Corporation
comprare levitra mastercard Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies.
Biovail Corporation
generico viagra soft in linea comrare | comprare il cialis soft senza ricetta | comprare il levitra senza ricetta

Comments are closed at this time.